**SpotitEarly Combines Canine Scent and AI to Detect Cancers, Launching at Disrupt**
In a groundbreaking move, Israeli startup SpotitEarly has un...
In a groundbreaking move, Israeli startup SpotitEarly has unveiled a revolutionary approach to cancer detection, combining the exceptional olfactory abilities of trained dogs with cutting-edge artificial intelligence. This innovative method aims to transform the landscape of early cancer screening by making it more accessible and affordable for a wider audience.
**The Concept and Technology**
SpotitEarly's pioneering technology involves analyzing human...
SpotitEarly's pioneering technology involves analyzing human breath samples using both AI and trained canines. The process begins with patients collecting a breath sample at home using a specially designed device. The sample is then shipped to SpotitEarly's lab, where 18 trained beagles use their acute sense of smell to detect cancer-specific odor signatures in the volatile organic compounds present in the breath. These compounds are essentially biological information from the blood in the lungs that travels into the air we exhale.
When a dog identifies cancer signatures in a sample, it sign...
When a dog identifies cancer signatures in a sample, it signals this to the lab by sitting next to it. Simultaneously, SpotitEarly's AI platform tracks and analyzes the physiological and behavioral signals of the dogs, collecting thousands of data points per second. This dual approach has shown remarkable accuracy, achieving a 94% sensitivity and specificity rate in detecting early-stage cancers, particularly for the four most common types: breast, colorectal, prostate, and lung[3][6][7].
**Market Impact and Expansion**
SpotitEarly's innovative method is not only highly accurate...
SpotitEarly's innovative method is not only highly accurate but also cost-effective. The company plans to make these at-home screening kits available through a physicians’ network, with each test priced at approximately $250. This is a significant departure from existing multi-cancer early detection tests, such as Grail's Galleri blood test, which costs around $950, and whole-body MRI scans that often exceed $2,000[6]. The startup has recently expanded into the U.S. market with a $20.3 million funding round led by Hanaco VC and other investors, further solidifying its position in the global healthcare landscape[3][4].
**Partnerships and Future Plans**
SpotitEarly is also collaborating with Hackensack Meridian H...
SpotitEarly is also collaborating with Hackensack Meridian Health to further research and validate its screening method. This partnership underscores the company's commitment to improving clinical outcomes and increasing early diagnosis rates, which are crucial for improving survival chances[3][12]. The company aims to make cancer screening more frequent and accessible, potentially enabling over 1 million annual tests in each SpotitEarly-powered facility[1].
**Launch at TechCrunch Disrupt 2025**
SpotitEarly's participation in TechCrunch Disrupt 2025 marks...
SpotitEarly's participation in TechCrunch Disrupt 2025 marks a significant milestone in its journey. The company's presentation at this prestigious event highlights its potential to disrupt traditional cancer screening methods and bring about a new era in early detection technology. With consumer availability planned for 2026, SpotitEarly is poised to revolutionize the way we approach cancer screening, making it more accessible and affordable for everyone[6].
In conclusion, SpotitEarly's unique blend of canine scent de...
In conclusion, SpotitEarly's unique blend of canine scent detection and AI technology is poised to change the face of cancer diagnostics. As the company continues to innovate and expand its reach, it holds great promise for improving healthcare outcomes and saving lives.
🔄 Updated: 10/10/2025, 3:00:50 PM
SpotitEarly’s launch at TechCrunch Disrupt 2025, unveiling its AI and canine-based cancer detection platform, has sparked significant investor enthusiasm, with the company recently securing a $20.3 million funding round led by Hanaco VC as it expands into the U.S. market[4]. While SpotitEarly is still privately held and not yet publicly traded, early-stage investors are reacting positively to its clinical promise—citing a 94% accuracy rate in detecting breast, colorectal, prostate, and lung cancers—and the potential for at-home test kits priced around $250[4]. Market analysts note that, if SpotitEarly pursues an IPO, the strong clinical validation and scalable, high-throughput model could position it favo
🔄 Updated: 10/10/2025, 3:10:46 PM
**Breaking News Update**: SpotitEarly's innovative cancer detection method, combining canine scent detection with AI, has achieved a remarkable 94% accuracy rate in identifying four common cancers—breast, colorectal, prostate, and lung—according to a recent clinical trial involving 1,400 participants[9][10]. The company, having raised $20.3 million in funding, plans to bring its at-home breath test kits to the U.S. market by 2026, with a projected price point of around $250 per test[6][9]. CEO Shlomi Madar highlighted the unique integration of AI and canine capabilities, noting that "The science is increasingly clear: Dogs can be trained to sniff out diseases, and especially cancer
🔄 Updated: 10/10/2025, 3:20:46 PM
SpotitEarly’s launch at Disrupt sparked positive market attention, with early investor interest visibly strengthening. Although the company is still private, its recent $20.3 million funding round led by Hanaco VC reflects strong confidence in its AI-canine cancer detection technology[1][3]. There have been no stock price movements reported yet as SpotitEarly prepares for an upcoming public investment round targeting accredited and regular investors soon[4].
🔄 Updated: 10/10/2025, 3:30:45 PM
**Breaking News Update**: SpotitEarly is set to launch its innovative cancer detection technology, combining canine scent and AI, at the TechCrunch Disrupt event from October 27 to 29 in San Francisco. This breakthrough technology, which has shown a 94% accuracy rate in detecting four common cancers, is poised to have a significant global impact by making early cancer detection more accessible and affordable, with plans to expand clinical studies internationally. According to SpotitEarly, its proprietary system could enable over 1 million annual tests per facility, potentially revolutionizing cancer screening worldwide[1][3][5].
🔄 Updated: 10/10/2025, 3:40:48 PM
SpotitEarly’s innovative cancer detection test, combining canine scent detection and AI, is currently **not FDA-approved** and remains under development and validation[1][7][9]. The company is actively working with regulatory bodies, including the Israeli Ministry of Health, and is preparing for an FDA pre-submission as part of a phased regulatory strategy, aiming for U.S. market entry possibly in 2026 pending approval[5][11][13]. CEO Shlomi Madar emphasized the goal to "make early cancer screening more accessible," with ongoing trials and collaborations at U.S. medical centers to further validate the technology before regulatory clearance[5][11].
🔄 Updated: 10/10/2025, 3:51:02 PM
At TechCrunch Disrupt 2025, SpotitEarly’s launch of an at-home breath test—combining AI and trained beagles—directly challenges existing multi-cancer early detection (MCED) players like Grail (Galleri blood test, ~$950) and imaging startups such as Prenuvo and Ezra (whole-body MRI, >$2,000), by offering a single test for four cancers at $250, with each additional cancer screened at a fraction of that price[2][5]. “Our proprietary bio-AI hybrid system achieved 94% accuracy in a 1,400-person clinical study, and we’re scaling to over 1 million annual tests per lab—something no pure tech o
🔄 Updated: 10/10/2025, 4:01:11 PM
SpotitEarly, a biotech startup founded in Israel, is generating global attention with its innovative cancer detection technology that combines trained canine scent detection and AI, achieving 94% accuracy in identifying early-stage breast, colorectal, prostate, and lung cancers in a 1,400-participant double-blind study published in Nature’s Scientific Reports[1][3]. The company, backed by $20.3 million from international investors including Hanaco VC and former Timberland CEO Jeff Swartz, announced its U.S. market entry in May and plans to launch at-home screening kits via physician networks next year at a competitive price of approximately $250 per test, aiming to make early cancer detection more accessible worldwide[1][3]. This breakthrough has prompted widesprea
🔄 Updated: 10/10/2025, 4:11:08 PM
**Breaking News Update**: SpotitEarly, a pioneering biotech firm, has successfully showcased its innovative cancer detection method at TechCrunch Disrupt 2025. The company's approach, which combines canine scent detection with AI, demonstrated a 94% accuracy rate in clinical trials involving 1,400 participants, according to a recent study published in *Nature* [1][2]. CEO Shlomi Madar emphasized the role of dogs as integral team members, highlighting their ability to process over a million tests annually from a single lab facility [5].
🔄 Updated: 10/10/2025, 4:21:13 PM
In a significant development, SpotitEarly's innovative approach to cancer detection has garnered substantial attention ahead of its showcase at TechCrunch Disrupt. While specific stock price movements for SpotitEarly aren't available due to its private status, the company has secured $20.3 million in funding, which is expected to boost its valuation and market presence. As investors await the launch of its at-home screening kits priced at around $250, industry analysts predict a potential surge in demand for affordable multi-cancer tests, potentially impacting the stock prices of competitors like Grail.
🔄 Updated: 10/10/2025, 4:31:30 PM
**Breaking News Update**: At TechCrunch Disrupt 2025, SpotitEarly unveiled its innovative cancer detection method, combining trained dogs' scent detection with AI technology, achieving a 94% accuracy rate in clinical trials. The company has secured $20.3 million in funding to expand its U.S. operations, with plans to integrate its technology through partnerships like the one with Hackensack Meridian Health. As part of this initiative, SpotitEarly CEO Shlomi Madar emphasized the company's commitment to transforming cancer detection, stating, "Dogs can be trained to sniff out diseases, and especially cancer, in humans" [1][3][5].
🔄 Updated: 10/10/2025, 4:41:29 PM
**Breaking News Update**: SpotitEarly, a pioneering startup combining canine scent detection with AI for cancer screening, is set to showcase its groundbreaking technology at TechCrunch Disrupt from October 27 to 29 in San Francisco. The company's innovative approach has garnered significant international attention, with recent clinical studies demonstrating a 94% accuracy rate in detecting early-stage cancers, including breast, colorectal, prostate, and lung cancers, among 1,400 participants[1][3]. As SpotitEarly expands globally, it aims to make its at-home screening kits widely available, potentially enabling over 1 million annual tests, thus transforming the global cancer detection landscape[3][4].
🔄 Updated: 10/10/2025, 4:51:34 PM
SpotitEarly is rolling out an at-home breath test combining AI analysis with 18 trained beagles—to detect breast, colorectal, prostate, and lung cancers with 94% accuracy, significantly undercutting competitors on price: a single cancer test will cost about $250, with additional cancers detected at a reduced rate, aiming to keep its multi-cancer panel well below Grail’s $950 Galleri test[1][2][7]. “Our methodology enhances accuracy beyond what a handler could achieve alone—the AI establishes a baseline for the entire dog team by monitoring heart rate and breathing patterns,” explained CEO Shlomi Madar, as the company prepares to showcase its technology at TechCrunch Disrupt in San Francisco, October 27
🔄 Updated: 10/10/2025, 5:01:28 PM
In a significant shift in the competitive landscape of cancer screening, SpotitEarly's innovative approach combining canine scent and AI is poised to disrupt the market with its at-home breath test. This technology offers a 94% accuracy rate for detecting common cancers, aiming to price its multi-cancer panel below competitors like Grail's Galleri test, which costs around $950, with SpotitEarly's initial test priced at approximately $250[1][2][5]. CEO Shlomi Madar emphasized the importance of making early detection more accessible, stating, "Dogs can be trained to sniff out diseases, and especially cancer, in humans," highlighting a potential game-changer in affordable cancer screening[2].
🔄 Updated: 10/10/2025, 5:11:45 PM
**Live Update (October 10, 2025):** SpotitEarly has entered the multi-cancer early detection race with a disruptive at-home breath test combining 18 trained beagles and AI—reporting 94% accuracy in a 1,400-participant study for breast, colorectal, prostate, and lung cancers, at a planned consumer price of just $250—dramatically undercutting rivals like Grail’s Galleri ($950) and whole-body MRI scans ($2,000+)[2][4][8]. CEO Shlomi Madar told TechCrunch, “Our proprietary system is a turnkey, high-throughput solution, potentially enabling over 1 million annual tests in each SpotitEarl
🔄 Updated: 10/10/2025, 5:21:41 PM
**LIVE UPDATE — Disrupt 2025, San Francisco:** SpotitEarly, fresh off a $20.3 million funding round led by Hanaco VC, is making waves at TechCrunch Disrupt with its at-home breath test that pairs trained beagles’ scent detection—capable of discerning cancer-linked compounds at parts-per-trillion levels—with its proprietary LUCID AI platform, which analyzes thousands of canine behavioral and physiological data points per second to deliver a 94% accuracy rate in detecting breast, colorectal, prostate, and lung cancers[1][2][3]. “The seamless integration of natural scent detection with advanced AI is a true breakthrough,” says Dr. Reef Einoch Amor, SpotitEarl